[PDF][PDF] ISPAD clinical practice consensus guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state.
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic
hyperosmolar state Page 1 ISPAD GUIDELINES ISPAD Clinical Practice Consensus …
hyperosmolar state Page 1 ISPAD GUIDELINES ISPAD Clinical Practice Consensus …
Effects of SGLT2 inhibitors on kidney and cardiovascular function
SGLT2 inhibitors are antihyperglycemic drugs that protect kidneys and the heart of patients
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
with or without type 2 diabetes and preserved or reduced kidney function from failing. The …
American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update
L Blonde, GE Umpierrez, SS Reddy, JB McGill… - Endocrine Practice, 2022 - Elsevier
Objective The objective of this clinical practice guideline is to provide updated and new
evidence-based recommendations for the comprehensive care of persons with diabetes …
evidence-based recommendations for the comprehensive care of persons with diabetes …
An overview of the cardiorenal protective mechanisms of SGLT2 inhibitors
T Salvatore, R Galiero, A Caturano, L Rinaldi… - International Journal of …, 2022 - mdpi.com
Sodium-glucose co-transporter 2 (SGLT2) inhibitors block glucose reabsorption in the renal
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …
proximal tubule, an insulin-independent mechanism that plays a critical role in glycemic …
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of …
TA Zelniker, SD Wiviott, I Raz, K Im, EL Goodrich… - The Lancet, 2019 - thelancet.com
Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …
[PDF][PDF] ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state.
ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the
hyperglycemic hyperosmolar state Page 1 ISPAD CLINICAL PRACTICE CONSENSUS …
hyperglycemic hyperosmolar state Page 1 ISPAD CLINICAL PRACTICE CONSENSUS …
SGLT2 inhibitors: a review of their antidiabetic and cardioprotective effects
Type 2 diabetes mellitus is a chronic metabolic disease associated with high cardiovascular
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
(CV) risk. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are the latest class of …
Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis
J Menne, E Dumann, H Haller, BMW Schmidt - PLoS medicine, 2019 - journals.plos.org
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent a new class of
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
oral hypoglycemic agents used in the treatment of type 2 diabetes mellitus. They have a …
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes: a systematic review and meta‐analysis of …
J Liu, L Li, S Li, Y Wang, X Qin, K Deng… - Diabetes, Obesity …, 2020 - Wiley Online Library
Aim To assess the effects of sodium‐glucoseco‐transporter‐2 (SGLT2) inhibitors on diabetic
ketoacidosis (DKA) in patients with type 2 diabetes. Materials and Methods We searched …
ketoacidosis (DKA) in patients with type 2 diabetes. Materials and Methods We searched …
[HTML][HTML] Perioperative diabetic ketoacidosis associated with sodium-glucose co-transporter-2 inhibitors: a systematic review
V Thiruvenkatarajan, EJ Meyer, N Nanjappa… - British journal of …, 2019 - Elsevier
Background Perioperative diabetic ketoacidosis (DKA) with near-normal blood glucose
concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated …
concentrations, termed euglycaemic ketoacidosis (EDKA), is an adverse effect associated …